Albiglutide Fragment

Description: Albiglutide, a marketed drug for the treatment of type 2 diabetes, is a long-acting agonist of the glucagon-like peptide-1 receptor. It is marketed by GlaxoSmithKline (GSK) in EU and US under the trade names of Eperzan and Tanzeum respectively. Albiglutide is a small protein/peptide consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4. Albiglutide can be used as a monotherapy (if metformin therapy is ineffective or not tolerated) or in combination with other antidiabetic drugs such as insulins. As of 2018, It is not clear if albiglutide affects a person's risk of death but GSK has announced that it intends to withdraw the drug from the worldwide market by July 2018 for economic reasons.

References: Expert Opin Biol Ther. 2016 Dec; 16(12):1557-1569; https://en.wikipedia.org/wiki/Albiglutide.